Drugs / CKD-331
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06088017 | Oct 2023 → Jan 2024 | hyperlipidemia | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT05634447 | Dec 2022 → Feb 2023 | hyperlipidemia | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT05335044 | May → Jun 2022 | — | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CKD-331 | “Period 1: CKD-331, D337 - A single oral dose of 2 tablets under fasting condition” NCT05634447 ↗ |
| Route | Oral | “QD, PO” NCT05335044 ↗ |